These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 28276811

  • 21. New treatment options for irritable bowel syndrome with predominant diarrhea.
    Weber HC.
    Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):25-30. PubMed ID: 27875419
    [Abstract] [Full Text] [Related]

  • 22. Eluxadoline-Associated Pancreatitis in a Post-Cholecystectomy Patient: A Case Report.
    Chhaparia A, Hammami MB, Vareedayah A, Schroeder K.
    Del Med J; 2017 Mar; 89(3):90-92. PubMed ID: 29894043
    [Abstract] [Full Text] [Related]

  • 23. Management of irritable bowel syndrome with diarrhea: focus on eluxadoline.
    Jones J, Lembo A, Heidelbaugh J, Kuritzky L, Lacy B.
    Curr Med Res Opin; 2021 Apr; 37(4):567-578. PubMed ID: 33566707
    [Abstract] [Full Text] [Related]

  • 24. Advancements in drug development for diarrhea-predominant irritable bowel syndrome.
    Dothel G, Barbaro MR, Raschi E, Barbara G, De Ponti F.
    Expert Opin Investig Drugs; 2018 Mar; 27(3):251-263. PubMed ID: 29451407
    [Abstract] [Full Text] [Related]

  • 25. Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline.
    Gawron AJ, Bielefeldt K.
    Clin Gastroenterol Hepatol; 2018 Mar; 16(3):378-384.e2. PubMed ID: 28804032
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study.
    Brenner DM, Sayuk GS, Gutman CR, Jo E, Elmes SJR, Liu LWC, Cash BD.
    Am J Gastroenterol; 2019 Sep; 114(9):1502-1511. PubMed ID: 31356229
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea.
    Abel JL, Carson RT, Andrae DA.
    Qual Life Res; 2019 Feb; 28(2):369-377. PubMed ID: 30267294
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea.
    Lacy BE, Gagnon-Sanschagrin P, Heimanson Z, Bungay R, Bellefleur R, Guérin A, Bumpass B, Borroto D, Joseph G, Dashputre AA.
    Adv Ther; 2024 Jun; 41(6):2253-2266. PubMed ID: 38619720
    [Abstract] [Full Text] [Related]

  • 36. Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome.
    Lacy BE.
    Aliment Pharmacol Ther; 2018 Oct; 48(8):817-830. PubMed ID: 30194692
    [Abstract] [Full Text] [Related]

  • 37. Rifaximin for the treatment of irritable bowel syndrome.
    Cremonini F, Lembo A.
    Expert Opin Pharmacother; 2012 Feb; 13(3):433-40. PubMed ID: 22251066
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Safety and Efficacy of Eluxadoline in Patients with Irritable Bowel Syndrome-Diarrhea With or Without Bile Acid Diarrhea: Open-Label Study.
    Vijayvargiya P, Breen-Lyles M, Nord SL, Maselli D, Busciglio I, Boinpally R, Muslin A, Carrothers TJ, Camilleri M.
    Dig Dis Sci; 2022 Aug; 67(8):3911-3921. PubMed ID: 35122592
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.